K
Kai-Chun Cheng
Researcher at Kaohsiung Medical University
Publications - 22
Citations - 485
Kai-Chun Cheng is an academic researcher from Kaohsiung Medical University. The author has contributed to research in topics: Visual acuity & Apoptosis. The author has an hindex of 9, co-authored 20 publications receiving 241 citations.
Papers
More filters
Journal ArticleDOI
Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.
Sheng-Kai Hsu,Chia-Yang Li,I-Ling Lin,Wun-Jyun Syue,Yih Fung Chen,Kai-Chun Cheng,Yen-Ni Teng,Yi-Hsiung Lin,Chia-Hung Yen,Chien-Chih Chiu +9 more
TL;DR: In this paper, the role of pyroptosis in cancer progression and the modulation of immunity is discussed, and the potential small molecules and nanomaterials that target pyroptic cell death mechanisms and their therapeutic effects on cancer are summarized.
Journal ArticleDOI
Unfolded Protein Response (UPR) in Survival, Dormancy, Immunosuppression, Metastasis, and Treatments of Cancer Cells
Sheng-Kai Hsu,Chien-Chih Chiu,Hans-Uwe Dahms,Chon-Kit Chou,Chih Mei Cheng,Wen-Tsan Chang,Kai-Chun Cheng,Hui-Min David Wang,I-Ling Lin +8 more
TL;DR: Regulating UPR through different molecular mechanisms may provide promising anticancer treatment options by suppressing cancer proliferation and progression and regulating dormancy and immunosuppression.
Journal ArticleDOI
The Role of Necroptosis in ROS-Mediated Cancer Therapies and Its Promising Applications.
Sheng-Kai Hsu,Wen-Tsan Chang,I-Ling Lin,Yih Fung Chen,Nitin Balkrushna Padalwar,Kai-Chun Cheng,Yen-Ni Teng,Chi-Huei Wang,Chien-Chih Chiu +8 more
TL;DR: This review concludes that several small molecules used in experiments and clinical practice eliminate cancer cells via the modulation of ROS and necroptosis, a caspase-independent form of cell death with features between apoptosis and necrosis.
Journal ArticleDOI
Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
TL;DR: These short-term results indicate that intravitreal injection of triamcinolone acetonide or bevacizumab can both improve visual acuity and decrease macular oedema temporarily in eyes with BRVO.
Journal ArticleDOI
Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion
TL;DR: Intravitreal injection of triamcinolone acetonide or bevacizumab can both lead to a significant improvement in visual acuity and a resolution of macular oedema in patients with CRVO, however, the significant effect was not permanent.